Current status of nerve growth factor antibodies for the treatment of osteoarthritis pain

Clin Exp Rheumatol. Sep-Oct 2017;35 Suppl 107(5):85-87. Epub 2017 Sep 28.

Abstract

Blockade of nerve growth factor (NGF) with antibodies is a promising strategy for treatment of chronic pain associated with osteoarthritis (OA). This narrative review describes the current status of NGF-blockade for the treatment of OA pain. We summarise briefly current evidence for the efficacy and risks of anti-NGF blockade. Two anti-NGF antibodies, tanuzemab and fasinumab, are in active development, with tanuzemabclose to completing Phase 3 trials in preparation for an application for approval for clinical use.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Humans
  • Nerve Growth Factor / antagonists & inhibitors*
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / physiopathology
  • Pain / drug therapy*

Substances

  • Antibodies, Monoclonal
  • NGF protein, human
  • Nerve Growth Factor